Restatement of Previously Issued Financial Statements - Additional Information (Detail) $ in Thousands	9 Months Ended
	Mar. 31, 2022 USD ($) Trails	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)
Targeted or Tracking Stock, Stock [Line Items]
Number of clinical stage candidates | Trails	3
Unrecognized tax benefits	$ 0
Revenue Recognised With Performance Obligation	29,300	$ 26,900
Accumulated Losses Since Inception	(358,096)			$ (319,705)
Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable	169,000
Deferred Revenue, Revenue Recognized	$ 96,700
Adjustments [Member]
Targeted or Tracking Stock, Stock [Line Items]
Accumulated Losses Since Inception			$ 3,900
Pass Through Services [Member]
Targeted or Tracking Stock, Stock [Line Items]
Percentage of reimbursement of pass through costs as revenue	100.00%
US License
Targeted or Tracking Stock, Stock [Line Items]
Deferred Revenue, Revenue Recognized	$ 64,500
Ex US License
Targeted or Tracking Stock, Stock [Line Items]
Deferred Revenue, Revenue Recognized	$ 32,200